secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2023-12-15T23:59:59+00:00
Accession:  0000950170-23-070743
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Therapeutics receives Nasdaq bid price noncompliance notice; also equity deficiency
--------------------------------------------------------------------------------

- Received Nasdaq notice on Dec 13, 2023 for failing to maintain $1.00 minimum bid price for 30 consecutive days.
- Has 180 days (until June 10, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.
- Also not compliant with Nasdaq's $2.5M minimum stockholders' equity requirement.
- If compliance not regained, common stock may be delisted to OTC markets, reducing liquidity.
- Considering options including a reverse stock split to cure bid price deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023070743/0000950170-23-070743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023070743/ktra-20231213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-070743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer